

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2015/044761 A1

(43) International Publication Date
2 April 2015 (02.04.2015)

(51) International Patent Classification:

A61K 31/20 (2006.01) A61P 19/02 (2006.01)
A61P 37/06 (2006.01) A61P 29/00 (2006.01)
A61P 17/06 (2006.01) A61P 13/00 (2006.01)

(21) International Application Number:

PCT/IB2014/001939

(22) International Filing Date:

29 September 2014 (29.09.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

P.405505 30 September 2013 (30.09.2013) PL

(71) Applicant: **WARSZAWSKI UNIWERSYTET MEDYCZNY** [PL/PL]; Al. Zwirki i Wigury 61, PL-02-091 Warszawa (PL).

(72) Inventors: **KOZIAK, Katarzyna**; ul. Bukowa 15, 02-708 Warszawa (PL). **ŻYŻYŃSKA-GRANICA, Barbara**; ul. Bartosška 22 m. 9, 02-382 Warszawa (PL). **FILIPEK, Sławomir**; ul. Dickens 22 m. 9, 02-382 Warszawa (PL). **NIEWIECZERZAL, Szymon**; ul. Lewartowskiego 5 m. 127, 00-190 Warszawa (PL). **TRZASKOWSKI, Bartosz**; ul. Petofiego 1A m. 20, 01-917 Warszawa (PL). **ZEGROCKA-STENDEL, Oliwia**; ul. Warszawska 89, 05-092 Łomianki (PL). **DUTKIEWICZ, Małgorzata**; ul. Sielecka 4 m. 13, 00-738 Warszawa (PL). **KRZECZYŃSKI, Piotr**; ul. Zeromskiego 36/42 m. 13, PL-01-831 Warszawa (PL). **KACZMAREK, Elżbieta**; Al. Wyzwolenia 8 m. 212, 00-570 Warszawa (PL). **WINI-**

ARSKA, Magdalena; ul. Gwiazdzista 13 m 127, PL-01-651 Warszawa (PL).

(74) Agent: **KRZYWDZIŃSKA, Ewa**; Instytut Farmaceutyczny, ul. Rydygiera 8, 01-793 Warszawa (PL).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))



WO 2015/044761 A1

(54) Title: DIAMINODECANEDIOIC ACID DERIVATIVE AS THE INHIBITOR OF IL-15 AND IL-2 ACTIVITY

(57) Abstract: The invention relates to 2,9-diaminodecanedioic acid derivative for use as the inhibitor of IL-15 and IL-2 receptors in the prevention and treatment of IL-15 and IL-2 overproduction related diseases.

Diaminodecanedioic acid derivative as the inhibitor of IL-15 and IL-2 activity.

5

Field of the invention

The present invention relates to the diaminodecanedioic acid derivative for the use in the treatment of the diseases related to interleukin 15 and interleukin 2 overproduction, such as
10 rheumatoid arthritis, psoriasis, inflammatory bowel disease, sarcoidosis, T-cell leukemias or transplant rejection.

Background of the invention

15 Interleukin 15 (IL-15) is the cytokine exerting pleiotropic activity towards immune system cells as well as other cell types. IL-15 exhibits broad spectrum bioactivity, therefore it is placed at the top of the pro-inflammatory cytokines cascade. The impairment of the mechanisms regulating the expression of the IL-15 results in the overproduction of this cytokine and contributes directly to the development of such pathologies as inflammatory processes,
20 autoimmune diseases, infections and neoplastic changes. IL-15 is considered a crucial cytokine in the etiology of rheumatoid arthritis (McInnes I.B. et al., Nat. Med. 2, 175-82 (1996); McInnes I.B. et al., Nat. Med. 3, 189-95 (1007); McInnes I.B. et al., Immunol Today 19, 75-9 (1998), psoriasis (Villadsen L.S. et al., J. Clin. Invest. 112, 1571-80 (2003), inflammatory bowel disease (Kirman I, Nielsen O.H., Am. J. Gastroenterol 91, 1789-1794 (1996); Sakai T. et al.,
25 Gastroenterology 114, 1237-1243 (1998)), sarcoidosis (Agostini C.T.L. et al., J. Immunol. 157, 910-8 (1996)) and T-cell leukemias (Dobbeling U. et al., Blood 92, 252-8 (1998)). Much attention is given to IL-15, on account of participation of this cytokine in transplant rejection (Baan C.C. et al., Transplant Proc. 31, 2726-8 (1999); Lewis E.C. et al., Cytokine 34, 106-13 (2006); Shi R. et al., Transpl. Immunol. 12, 103-8 (2004); Ferrari-Lacraz S. et al.,
30 Transplantation 82, 1510-7 (2006); Zheng X.X. et al., Transplantation 81, 109-16 (2006)).

Significant involvement of IL-15 in the development of the pathogeneses of the aforementioned afflictions suggests that targeting this cytokine signaling pathway can reduce or eliminate the occurrence of IL-15-related disorders. This strategy has been proved lately by a number of biological assays. Reduction of IL-15-mediated biological responses, using the
35 soluble receptor IL-15R α (Liew F.Y., McInnes I.B., Ann. Rheum. Dis. 61 Supl. 2, ii100-2 (2002); Ruchatz H. et al., J Immunol. 160, 5664-60 (1998); Smith X.G. et al., J. Immunol. 165, 3444-50 (2000); Wei X et al., J. Immunol. 167, 277-82 (2001)), antibodies inhibiting receptor IL-2/IL-15R β (Morris J.C., Proc. Natl. Acad. Sci. USA 103, 401-6 (2001); Tinubu S.A. et al., J. Immunol. 153, 4330-8 (1994), antibodies inhibiting IL-15 (Villadsen L.S. et al. J. Clin. Invest. 112, 1571-80 (2003) or modified IL-15 molecule of competitive antagonist activity (Ferrari-Lacraz S. et al., J.
40 Immunol. 173, 5818-26 (2004); Kim Y.S. et al., J. Immunol. 160, 5742-8 (1998)) always resulted

in the alleviation of the disease symptoms. The experimental therapies demonstrated decreased occurrence of collagen-induced rheumatoid arthritis incidence in mice (Ruchatz H. et al., J Immunol. 160, 5664-60 (1998); Ferrari-Lacraz S. et al., J. Immunol. 173, 5818-26 (2004); Kim Y.S. et al., J. Immunol. 160, 5742-8 (1998)) and primates (Liew F.Y., McInnes I.B., Ann. Rheum. Dis. 61 Supl. 2, ii100-2 (2002)), attenuation of psoriasis symptoms in the mice model of the disease (Villadsen L.S. et al., J. Clin. Invest. 112, 1571-80 (2003)), reduction of carrageenan-induced inflammation in mice (Wei X et al., J. Immunol. 167, 277-82 (2001)) and, also in mice, prolonged survival of heart allotransplants (Smith X.S. et al., J. Immunol. 165, 3444-50 (2000); Tinubu S.A. et al., J. Immunol. 153, 4330-8 (1994) and islets of Langerhans (Ferrari-Lacraz S. et al., J. Immunol. 173, 5818-26 (2004)). Currently adopted strategies, based on inhibiting the IL-15, seem to be effective, but none of them has been approved for clinical use so far. The most advanced and promising, from the medical application point of view, are the trials aimed at the inhibition of the IL-15 activity by anti-IL-15 human antibodies (HuMax-IL15, AMG-714) (Baslund B. et al., Arthritis Rheum 52, 2686-92 (2005)). However, the matter of serious concern is the effect of 'reverse signaling' (Budagian V. et al., J. Biol. Chem. (2004)). It is assumed that the antibody HuMax-IL15 and IL-15 complex can itself induce the cell response, thus limiting the therapeutic effectiveness of this antibody directed toward IL-15 neutralization (Budagian V. et al. Cytokine Growth Factor Rev. 17, 259-80 (2006).

In addition, our unpublished results demonstrate significant angiogenic activity of IL-15. The participation of IL-15 in angiogenesis *in vivo* has already been reported (Angiolillo A.L. et al., Biochem. Biophys. Res. Commun. 233, 231-7 (1997); Kuniyasu H. et al., Pathobiology 69, 86-95 (2001)), but our recent outcomes have also shown IL-15-induced proliferation and migration of endothelial cells. The identification of another angiogenic factor was not surprising, because its presence had already been detected in rheumatoid arthritis, where the impaired mechanism of angiogenesis is considered to be the main pathogenesis of this illness.

Rheumatoid arthritis (RA) is the most common systemic disease of connective tissue, which affects on average about 1% of the world's population. Recent estimates have shown higher prevalence in women than in men (3:1). The highest prevalence of RA has been reported in the 30-60 age range. According to the estimates, about 30% of people afflicted with RA suffer from severe symptoms and within several years end up with a disability. The average life span of people suffering from RA is about 10 years shorter, according to the statistical data. It is thought that the onset of RA results from the complex combination of many factors, such as genetic predisposition, impaired innate and acquired immune response and environmental components. Pharmacological treatment of RA, currently available on the medical market, does not remove the cause of the disease. Non-steroidal anti-inflammatory drugs (NSAIDs) are medications, which as well as having pain-relieving (analgesic) effects, have the effect of reducing the inflammation, when used over a period of time. They suppress the symptoms of the disease, but do not stop the progress of the illness.

Among the disease-modifying antirheumatic drugs (DMARDs), the first line treatment in RA is methotrexate. The other synthetic DMARDs are leflunomide, sulfasalazine,

hydroxychloroquine, D-penicillamine, gold salts, azathioprine, cyclosporine and cyclophosphamide. However, even in patients responding to the treatment, the disease progresses and diminished medical efficacy is observed after long term treatment.

The other class of DMARDs are the biologic medical products. Among the drugs
5 available on the pharmaceutical market, the inhibitors of tumor necrosis factor (TNF) are to be mentioned:

- infliximab (chimeric anti-TNF monoclonal antibody);
- etanercept (fusion protein, consisting of the extracellular receptor domain p75 for TNF and the Fc fragment of the human antibody IgG1);
- 10 - adalimumab (human anti-TNF monoclonal antibody),

as well as the inhibitors of other proteins:

- anakinra, IL-1 receptor antagonist;
- abatacept, fusion protein composed of the Fc region of the immunoglobulin IgG1 fused to the extracellular domain of CTLA-4. By binding B7-1 and B7-2 co-stimulating molecules
15 located on the antigen-presenting cells it inhibits the co-stimulatory signal transduction by CD28 on T cells;
- rituximab, chimeric monoclonal antibody against the protein CD20 primarily found on the surface of mature B cells acting by eliminating B cells.

Tocilizumab, humanized monoclonal antibody against interleukin 6 receptor, has been
20 approved for the European pharmaceutical market as the first IL-6 inhibitor.

Positive results of phase II clinical trials carried out by Amgen company with AMG-714 (previously HuMax-IL15) - human monoclonal antibody that targets IL-15, were disclosed in 2004 (McInnes, I., et al.). However, to date there is no available information about the phase III clinical trials.

25 The introduction of the biologic medical products into rheumatoid arthritis therapy is considered big progress in the RA treatment, but these biologics (usually used in a combination with methotrexate of cytostatic and immunosuppressive properties) are only effective in limiting the disease symptoms and delaying joint degradation in about 30% of treated patients.

Due to the limited therapeutic effects and high production costs of currently available
30 biologic medical products, the demand for an efficacious anti-RA drug of new generation still remains valid. Ongoing research is aimed at discovering new molecular mechanisms for targeted therapies.

Peptides of modified sequences mimicking IL-15 (revealed, among others, in WO 2006/029578 and WO 2010/037351) have also been proposed as potential pharmaceuticals in
35 the rheumatoid arthritis treatment. These peptides are supposed to bind to the receptor IL-15Ra subunit, which should result in the inhibition of T cells proliferation, diminished TNF- α induction

as well as expression of IL-8 and IL-6. To date the efficacy of these new compounds has not been proved in clinical studies.

There are other cytokines, which participate in the pathogenesis of inflammatory diseases, induced by interleukin 15 overproduction.

5 In the complex network of the immune mediators, interleukin 2 (IL-2) is regarded the pivotal cytokine controlling proliferation and differentiation of the immune cells. IL-2 activates, among others, proliferation and differentiation of T lymphocytes, differentiation of T lymphocytes towards cytotoxic T lymphocytes, growth and differentiation of B lymphocytes, activation and proliferation of NK cell, and macrophages activation. Under physiological conditions IL-2 is not
10 detected in a blood serum. Due to its contribution to the activation and stimulation of the effector function of the immune cells, this cytokine is considered one of the chief inflammatory mediators in the autoimmune diseases. IL-2 is released predominantly by activated T helper lymphocytes (CD4+), it is also secreted by CD8+ T lymphocytes, dendritic cells and thymus-derived lymphocytes (128). The downstream effect of IL-2 occurs through its high-affinity binding to the
15 receptor IL-2R, consisting of three subunits: IL-2R α subunit, which is IL-2 specific and IL-2R β and IL-2R γ subunits, which are shared with IL-15. Serum soluble form of IL-2 receptor (sIL-2R α , Tac peptide) is released into circulation by the immune cells. Under physiological conditions its concentration in a blood serum is at a very low level, but it is significantly elevated in some pathologies, for example in the autoimmune diseases, inflammations, some types of leukemia,
20 and allogenic transplant rejections. It has been observed, the level of sIL-2R α correlates with the RA progression, there is also the evidence it induces the expression of IL-15 (Release of sIL-2R alpha from and activation of native human peripheral blood mononuclear cells by recombinant IL-15. Treiber-Held S, Stewart DM, Barraclough HA, Kurman CC, Nelson DL. Clin Immunol Immunopathol. 1996 Jul;80(1):67-75).

25 Currently, different components of the IL-2/IL-2R complex and/or their antagonists, for example, murine monoclonal antibodies (anti-TAC-M) directed toward the human sIL-2R α receptor, are used in the medical treatment. Due to their strong immunogenicity, humanized monoclonal antibodies (anti-TAC-H) recently have been engineered and introduced into clinical practice. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases,
30 and in the prevention of allograft rejection: a 25-year personal odyssey, Waldmann TA. J Clin Immunol. 2007 Jan; 27(1): 1-18. The monoclonal antibodies prevent IL-2 binding, among others, to T lymphocytes, thus hampering IL-2 mediated cell response involved in the process of allograft rejection. (WWW.drugbank.ca/drugs/BTD00007).

35 A need to design a new drug based on a small synthetic molecule has motivated the authors of the present invention to alter the concept of the treatment of the IL-15 overproduction related diseases. This approach relates to the inhibition of the IL-15 biological activity by a compound selectively binding to IL-15R α receptor. According to the current state of knowledge and our own unpublished results, the strategy, while implemented, should reduce the pro-inflammatory cascade as well as angiogenesis caused by pro-inflammatory cytokine IL-15. The

additive synergism may be the most likely the explanation of the mechanism, so far unrecognized, of the inhibition of IL-15 biological activity by the biologicals.

The known small chemical molecules of potential application in rheumatoid arthritis, which interfere with the interaction of the receptor IL-15R α and its ligand (IL-15) are only phenylpyrazole anilide derivatives, disclosed by Ushio H. et al. in Letters in Drug Design Discovery, 5, 292-296 (2008). The molecule Y-320, belonging to the aforementioned group of compounds of proven high bioavailability and *in vitro* activity, inhibits IL-15-induced T cells activity.

The aim of the present invention was to select a molecule, which would effectively inhibit the biological activity of both IL-15 and IL-2 by selective binding to IL-15 specific IL-15R α receptor and concomitant blocking IL-2R β as well as IL-2R γ receptor subunits shared by these two cytokines.

Summary of the invention

The identification of a chemical compound which will fit in the IL-15R α receptor was facilitated due to the evaluation of the receptor domain structure, which is of key importance while binding to IL-15 (Wei X. et al., J. Immunol. 167, 277-82 (2001)). The search for small chemical molecules fitting in the IL-15 specific receptor domain was carried out on the basis of the model of the [IL-15R α – IL-15] complex structure, elaborated on the basis of the crystal structure of the complex fragment (2Z3Q code of Protein Data Bank). The assignment of receptor binding sites pharmacophores, while considering specific interactions with IL-15, was enabled due to the determination of the 3D structure of the [IL-15R α – IL-15] complex. It was followed by the search of small molecules data base ZINC, embracing about 20 million chemical compounds, to find the molecules which can meet the structural requirements for pharmacophores. The screening included more than 10 thousand compounds fulfilling the established criteria. The calculations were also carried out in order to theoretically predict the binding affinity and strength of the selected compounds and the receptor active site. Molecular docking of the chosen molecules was performed using GLIDE software. While docking, the IL-15 binding site of the receptor remained rigid, but the molecule was able to undergo conformational changes due to the modifications of rotating chemical bonds. Additional docking carried out for the pre-selected 500 molecules allowed the induction fitting in of the two interacting partners (protein receptor and small molecule).

Using the above described screening methods, one compound has been selected. *In vitro* studies proved its efficiency in inhibiting IL-15 and IL-2-induced cell responses.

The present invention provides 2,9-diaminodecanedioic acid as the inhibitor of IL-15R α and shared by IL-15 and IL-2, IL-2R β IL-2R γ receptor subunits, which can be used in the prevention and treatment of the diseases related to interleukin 15 and interleukin 2 overproduction.

40

Brief description of the figures

Fig. 1 shows the effect of 2,9-diaminodecanedioic acid on proliferation of IL-15-stimulated PBMC.

- 5 Fig. 2 shows the effect of 2,9-diaminodecanedioic acid on proliferation of IL-2-stimulated PBMC.
Fig. 3 shows the effect of 2,9-diaminodecanedioic acid on IL-15-induced TNF- α synthesis in PBMC.

Fig. 4 shows the effect of 2,9-diaminodecanedioic acid on IL-2-induced TNF- α synthesis in PBMC.

- 10 Fig. 5 shows the effect of 2,9-diaminodecanedioic acid on IL-15-induced IL-17 synthesis in PBMC.

Fig. 6 shows the effect of 2,9-diaminodecanedioic acid on IL-2-induced IL-17 synthesis in PBMC.

15 Disclosure of the invention

2,9-Diaminodecanedioic acid derivative for use according to the invention can be 2,9-diaminodecanedioic acid as the single optical isomer thereof or the mixture of optical isomers at any ratio, as for example racemic mixture.

- 20 The present invention encompasses the use of 2,9-diaminodecanedioic acid as the racemic or the non-racemic mixture, the single optical isomer as well as the pharmaceutically acceptable salts and aliphatic esters thereof, such as dimethyl or diethyl ester.

2,9-Diaminodecanedioic acid, also referred to as 2,9-diaminosebacic acid, is commonly known as the starting material in peptides and polyamides synthesis.

- 25 The single optical isomers of 2,9-diaminodecanedioic acid can be obtained according to any method known to those skilled in the art, such as chiral HPLC or enzymatic or using chiral auxiliary resolution or they can be synthesized in a enantioselective manner from the chiral starting compounds.

- 30 2,9-Diaminodecanedioic acid derivatives can be also prepared and used as the pharmaceutically acceptable salts with acids. The term „pharmaceutically acceptable salts” refers to the salts formed with the pharmaceutically acceptable inorganic and organic acids. The inorganic acids belong to the group comprising, for example, hydrochloric, hydrobromic, sulfuric and nitric acids. The organic acids belong to the group comprising, for example, fumaric, maleic, phosphoric, glycolic, lactic, adipic, ascorbic, salicylic, succinic, tartaric, acetic, citric,
35 formic, benzoic, malonic, p-toluenesulfonic, methanesulfonic, naphthalene-2-sulfonic, benzenesulfonic acids and the others. The preferred salts of 2,9-diaminodecanedioic acid derivatives are the salts with hydrochloric acid.

In the preferred embodiment of the invention, 2,9-diaminodecanedioic acid derivative is ($\pm$)-2,9-diaminodecanedioic acid hydrochloride.

40

The preferred aliphatic esters of 2,9-diaminodecanedioic acid for use according to the invention are the esters with C₁₋₃ alcohols, such as dimethyl or diethyl ester.

Biological activity of 2,9-diaminodecanedioic acid derivatives for the use according to the present invention has been proved by the methods *in vitro*. The results have demonstrated the efficacy of 2,9-diaminodecanedioic acid derivatives in inhibiting IL-15-induced cell proliferation and blocking IL-15-induced TNF- α and IL-17 synthesis. The same inhibitory effect of the said compounds has been observed when cells were stimulated with IL-2.

These results suggest that 2,9-diaminodecanedioic acid derivative can be used to hamper IL-15 and IL-2-induced excessive cells' responses, due to blocking IL-15 specific IL-15R α receptor and IL-2R β and IL-2R γ receptor subunits, shared by these two cytokines.

In particular, 2,9-diaminodecanedioic acid derivative can be used in the prevention and treatment of the diseases from the group comprising rheumatoid arthritis, psoriasis, inflammatory bowel disease, sarcoidosis, T-cell leukemias and transplant rejection.

Preferably, 2,9-diaminodecanedioic acid derivative can be used in the treatment of rheumatoid arthritis.

According to the invention, 2,9-diaminodecanedioic acid derivative can be administered to an individual in the need of such a treatment, in particular to a human, at therapeutically effective dose.

The term 'treatment' refers to the suppression of a state, a disorder or a disease, which means inhibition, reduction or delay of the disease development, recurrence of the illness or at least one of its symptoms, or a recovery, meaning the regression of a state, a disorder or a disease or at least one of its symptoms.

The term 'therapeutically effective dose' refers to the amount of the compound sufficient to produce a therapeutic response when administered to an individual in order to cure a state, a disorder or a disease. The 'therapeutically effective dose' will vary depending on the nature of the selected compound and the route of its administration, a kind of a disease and its status, age, body weight, physical condition, susceptibility to the treatment of the patient, and it can be recommended by a skilled physicians on the basis of their own experience and the results of clinical trials.

The daily therapeutic dose of 2,9-diaminodecanedioic acid derivative can be administered as a single dose or divided doses administered in certain intervals of time, for example as two, three, four or more daily doses.

Although the administration of 2,9-diaminodecanedioic acid derivative *per se* may be considered, in general it will be used as active ingredient of the pharmaceutical formulation, of the appropriate finished dosage form suited to the particular route of administration.

Another embodiment of the present invention relates to the use of 2,9-diaminodecanedioic acid derivative for manufacturing of the pharmaceutical formulation for the prevention or treatment of the diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel disease, sarcoidosis, T-cell leukemias or transplant rejection.

The other embodiment of the present invention relates to the pharmaceutical formulation comprising 2,9-diaminodecanedioic acid derivative as the active ingredient and the pharmaceutically acceptable carriers and/or excipients for the prevention or treatment of the diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel disease, sarcoidosis, T-cell
5 leukemias or transplant rejection.

The pharmaceutical formulation – except for the active ingredient – may also contain traditional pharmaceutically acceptable carriers and/or excipients which are inert and do not interact with the active ingredient.

The pharmaceutical composition may be formulated in any pharmaceutical form suitable
10 for the systemic administration, for example oral administration, such as tablets and capsules, starch capsules, coated tablets or enteric tablets; as powders or granules; as a solution, a suspension or an emulsion. Tablets and capsules for oral administration may contain excipients routinely used in pharmaceutical practice, such as binders, diluents, disintegrants or lubricants. The tablets may be coated by any method known in the art. Liquid pharmaceutical compositions
15 for oral administration may be manufactured as, for example, aqueous or oily suspensions, solutions, emulsions, syrups and elixirs or they may be produced as dry substances for the preparation of solutions or suspensions *ex tempore* with water or other suitable diluent. Liquid pharmaceutical formulations may contain excipients routinely used in pharmaceutical practice, such as dispersing and emulsifying agents, non-aqueous carriers (they may comprise eatable
20 oils) or preservatives. The selection and amount of the excipients depends on the pharmaceutical dosage form and the route of drug administration. The pharmaceutical composition may be formulated into any suitable pharmaceutical form, by any method known in the art, using any pharmaceutically acceptable carriers, diluents, fillers and other excipients.

The pharmaceutical formulation for oral administration may be formulated, in particular,
25 as capsules. In such case, the active substance is combined with the carrier and the resulting composition is used to fill in gelatin shells. The gelatin capsules can be manufactured as having soft or hard gelatin shells, depending on the composition of gel mass used in the production process. Soft capsules' gel mass consists of plasticizers, such as glycerol, sorbitol; preservatives, such as benzoic acid, its salts and alkyl hydroxybenzoates, colorants and flavors.
30 The capsules' filling may be used as oily solution, suspension or emulsion. The suitable diluents embrace, for example castor oil, coconut oil, olive oil, palm oil, corn oil, arachis oil, synthetic and natural triglycerides of fatty acids, unsaturated medium-chain fatty acids, modified long-chain fatty acids, glycol esters, polyethylene glycols and others. Suitable excipients comprise tensides, for example lecitin, mono- and diglycerides, fatty acids esters with polyoxoethylene
35 sorbitane.

The pharmaceutical formulation suitable for parenteral administration, for example for intramuscular, subcutaneous or intravenous administration, may be used as a ready suspension, lyophilizate, suspension *ex tempore* or concentrate for intravenous infusions. These formulations may be formulated as unit dosage forms in ampoules, initially filled syringes,
40 low capacity infusions, or in multi-dosage containers consisting of preservatives and carriers,

diluents, stabilizers and/or dispersing agents. The carriers suitable for the intravenous administration of the pharmaceutical formulation comprise, for example, sterile aqueous solutions, such as the solution of physiological salt, the solutions of carbohydrates, for example, glucose, mannitol, dextrose, lactose and aqueous buffer solutions, for example, phosphate buffers. The pharmaceutical composition may also contain other excipients routinely used to maintain isoosmoticity, antioxidants, preservatives and others. Alternatively, the active ingredient may be used as the powder obtained due to isolation of a solid compound under septic conditions or by lyophilisation from the solvent, for the preparation of suspensions *ex tempore* in a suitable diluent, for example, sterile water deprived of pyrogenic substances.

The biological activity of 2,9-diaminodecanedioic acid derivative, inhibiting IL-15 and IL-2-induced cells' response has been proved during *in vitro* studies. The results have also demonstrated inhibition of cell proliferation as well as reduced synthesis of TNF- α and IL-17, induced by the said cytokines. When this effectiveness is proved *in vivo* studies in animal model of the diseases, 2,9-diaminodecanedioic acid derivative will have the potential to be used in the prevention and treatment of IL-15 overproduction related diseases and inflammations, such as rheumatoid arthritis, psoriasis, inflammatory bowel disease, sarcoidosis, T-cell leukemias or transplant rejection.

Biological studies

In vitro studies

All experiments were carried out on peripheral blood mononuclear cells (PBMC) from healthy donors. The cells were isolated under the standard protocol regarding density gradient centrifugation. According to the general protocol, 6 ml of blood was layered on 3 ml of Lymphoprep (Axis-shield, Norway), then centrifuged at 800 x g for 15 min. The layer of PBMC was collected, the cells were washed twice with phosphate buffered saline (PBS) (BIOMED-LUBLIN, Poland) and suspended in medium RPMI1640 (Gibco, Great Britain), containing 10 mM HEPES (Sigma, USA), 10% fetal calf serum (BIOMED-LUBLIN, Poland) and antibiotic (streptomycin sulfate, penicillin G sodium, amphotericin B, PAA, Austria).

2,9-Diaminodecanedioic acid (R6) was initially selected at the screening stage, on the basis of the three dimensional structure of the model of [IL-15R $\alpha\beta\gamma$ – IL-15] protein complex. 2,9-Diaminodecanedioic acid was used as salt with hydrochloric acid.

In all the *in vitro* experiments non stimulated PBMC were used as the control. The inhibition efficacy was assessed in relation to the cells stimulated with IL-15 or IL-2.

Example 1

Effect of 2,9-diaminodecanedioic acid on proliferation of interleukin 15 or interleukin 2-induced PBMC

PBMC proliferation was evaluated using commercially available BrdU Cell Proliferation Assay (Calbiochem, Merck, Germany). PBMC were seeded in a 96-well plate (25×10^3 cells in 200 μ l of the culture medium/well). The next day the cells were treated with the tested compound at final concentrations: 20 μ M and 100 μ M. After 30 min. incubation with 2,9-diaminodecanedioic acid, cells were stimulated with IL-15 at the final concentration 5 ng/ml or IL-2 at the final concentration 5 ng/ml. Cells were incubated for 4 days, then for last 24 h bromodeoxyuridine (BrdU) was added to the culture medium at the concentration recommended by the manufacturer. After the completion of the incubation cells were centrifuged (10 min., 160xg) and fixed. Further experimental steps were performed according to the manufacturer's protocol.

The effects of 2,9-diaminodecanedioic acid at different concentrations on IL-15 and IL-2-induced PBMC proliferation are presented in Fig. 1 and Fig. 2 respectively. The results are expressed as the percentage change of proliferating cells with regard to the control cells stimulated with IL-15 or IL-2.

Example 2

Effect of 2,9-diaminodecanedioic acid on IL-15 or IL-2-induced TNF- α synthesis in PBMC

The evaluation of TNF- α synthesis in IL-15-stimulated PBMC was performed using the ELISA method and commercially available tests (R&D, USA). The experiment was carried out strictly according to the manufacturer's recommendations.

PBMC were seeded in a 24-well plate (2×10^6 cells in 1 ml of the culture medium/well), treated with the tested compound and after 30 min stimulated with IL-15 (5 ng/ml) or IL-2 (5 ng/ml). After 48 h incubation, the culture medium was collected from each well to determine the TNF- α concentration, cells were harvested and lysed, and the concentration of total protein was measured in cell lysates. The obtained values of TNF- α concentration were calculated for 1 mg of protein. The results are expressed as the percentage change of the concentration of TNF- α synthesized in PBMC with regard to the control cells stimulated with IL-15.

The effect of 2,9-diaminodecanedioic acid at different concentrations (20 μ M, 50 μ M, 100 μ M and 200 μ M) on IL-15-induced TNF- α synthesis in PBMC is depicted in Fig. 3. The effect of 2,9-diaminodecanedioic acid at 100 μ M concentration on IL-2-induced TNF- α synthesis in PBMC is depicted in Fig. 4.

2,9-Diaminodecanedioic acid significantly reduces IL-15 or IL-2-induced TNF- α synthesis in PBMC in comparison with the IL-15 and IL-2 stimulated control cells.

Example 3

Effect of 2,9-diaminodecanedioic acid on IL-15 or IL-2-induced IL-17 synthesis in PBMC

The evaluation of the IL-17 synthesis in IL-15 or IL-2-stimulated PBMC was performed using the ELISA method and commercially available tests (R&D, USA). The experiment was carried out strictly according to the manufacturer's recommendations.

PBMC were seeded in a 24-well plate (2×10^6 cells in 1 ml of the culture medium/well),
5 treated with the inhibitor, after 30 min. stimulated with IL-15 (5 ng/ml) or IL-2 (5 ng/ml). After 48 h incubation, the culture medium was collected from each well to determine the IL-17 concentration, cells were harvested and lysed, and the concentration of total protein was measured in cell lysates. The obtained values of IL-17 concentration were calculated for 1 mg of protein. The results are expressed as the percentage change of the concentration of IL-17
10 synthesized in PBMC with regard to the control cells stimulated with IL-15 or IL-2.

The effect of 2,9-diaminodecanedioic acid at different concentrations (20 μ M, 50 μ M, 100 μ M and 200 μ M) on the IL-15-induced IL-17 synthesis in PBMC is depicted in Fig. 5. The effect of 2,9-diaminodecanedioic acid at 100 μ M concentration on IL-2-induced IL-17 synthesis in PBMC is depicted in Fig. 6.

15 2,9-Diaminodecanedioic acid significantly reduces IL-15-induced IL-17 synthesis in PBMC in comparison with IL-15-stimulated control cells. Strong inhibitory effect of 2,9-diaminodecanedioic acid on IL-17 synthesis is also observed in cells stimulated with IL-2.

Discussion

20

1. Initial studies based on the assessment of 2,9-diaminodecanedioic acid cytotoxicity and efficacy of inhibition of IL-15 or IL-2-induced cell proliferation.

Increased cell proliferation is one of the characteristic responses to IL-15 or IL-2 stimulation. Selective blocking of the IL-15 specific receptor IL-15R α as well as shared by IL-15
25 and IL-2, IL-2R β and IL-2R γ receptor subunits, results in the inhibition of biological activity of the said cytokines. As a consequence, IL-15 or IL-2-induced increase of cell proliferation does not occur. The effect of 2,9-diaminodecanedioic acid on proliferation of peripheral blood mononuclear cells (PBMC) isolated from blood of healthy donors was evaluated in the assay using a fluorescent CFSE dye (Molecular Dynamics, Great Britain) and in the
30 bromodeoxyuridine incorporation test (BrdU) (BrdU Cell Proliferation Assay, Calbiochem, USA). PBMC population consists of several cell types, among others, there are lymphocytes and monocytes. Due to expression of IL-15 and IL-2 receptors on the surface of the membrane, extensive proliferation of these cells occurs in response to interleukin 15 or interleukin 2 stimulation. The inhibition of cell proliferation in the presence of the tested compound can be a
35 visible sign of the cells' death caused by the cytotoxic or apoptotic activity of the analyzed compound. The effect of 2,9-diaminodecanedioic acid on cells' viability was tested measuring the lactate dehydrogenase (LDH) concentration in the culture medium and cultured cells (CytoTox 96 Non-Radioactive Cytotoxicity Assay, Promega, USA). LDH is a cytosolic enzyme which under physiological conditions is not released from cells. However, when a cell
40 membrane damage or cell death occurs, LDH enzyme is released into the matrix. Increased

LDH activity in the culture medium correlates with the increased number of dead cells resulting from the cytotoxic effect of the tested compound. LDH activity measured in cell lysates is used for the assessment of a number of living cells. The results of the following study has demonstrated biological activity of 2,9-diaminodecanedioic acid, which inhibits IL-15 or IL-2-
5 induced PBMC proliferation and does not trigger the apoptotic pathway. The experiments were repeated three time on PBMC form different donors.

2. The assessment of inhibitory effectiveness of 2,9-diaminodecanedioic acid on IL-15 and IL-2-
10 induced TNF- α and IL-17 syntheses.

Peripheral blood mononuclear cells (PBMC) respond to IL-15 or IL-2 stimulation not only by increased proliferation, but also by synthesizing many pro-inflammatory cytokines, among others, for example, TNF- α and IL-17. The inhibition of IL-15 and IL-2 biological activity should
15 result in the reduced cell proliferation and decreased syntheses of TNF- α and IL-17.

2,9-Diaminodecanedioic acid at different concentrations was used to assess its effect on IL-15 and IL-2-induced other cytokines syntheses. The biological activity of 2,9-diaminodecanedioic acid was evaluated measuring the TNF- α and IL-17 concentrations in the culture media collected after the completion of the incubation, using the immunoenzymatic
20 ELISA tests.

The tests results prove the inhibition of the TNF- α and IL-17 syntheses and they serve as the following evidence of 2,9-diaminodecanedioic acid biological activity.

Claims

1. 2,9-Diaminodecanedioic acid derivative for use as the inhibitor of IL-15 and IL-2 receptors in the prevention and treatment of IL-15 and IL-2 overproduction related diseases.
2. 2,9-Diaminodecanedioic acid derivative for use according to claim 1, wherein the derivative is 2,9-diaminodecanedioic acid is the optical isomer, the mixture thereof, including the racemic mixture, pharmaceutically acceptable salt or ester with aliphatic alcohol.
3. 2,9-Diaminodecanedioic acid derivative for use according to claim 1, wherein the derivative is ($\pm$)-2,9-diaminodecanedioic acid hydrochloride.
4. 2,9-Diaminodecanedioic acid derivative for use according to claim 1, wherein the disease is rheumatoid arthritis, psoriasis, inflammatory bowel disease, sarcoidosis, T-cell leukemias or transplant rejection.
5. 2,9-Diaminodecanedioic acid derivative for use according to claim 1, wherein the disease is rheumatoid arthritis.
6. 2,9-Diaminodecanedioic acid derivative for use according to claim 1, wherein 2,9-diaminodecanedioic acid derivative is to be administered in a therapeutically effective dose to an individual in need of such a treatment.
7. 2,9-Diaminodecanedioic acid derivative for use according to claim 1, wherein the therapeutically effective dose of 2,9-diaminodecanedioic acid derivative is to be administered as the active ingredient of the pharmaceutical formulation or a single dosage form.
8. Use of 2,9-diaminodecanedioic acid derivative for manufacturing of the pharmaceutical formulation the prevention and treatment of the diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel disease, sarcoidosis, T-cell leukemias or transplant rejection.
9. Pharmaceutical formulation comprising therapeutically effective amount of 2,9-diaminodecanedioic acid derivative as the active ingredient and pharmaceutically acceptable carriers and/or excipients for use in the prevention and treatment of the diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel disease, sarcoidosis, T-cell leukemias or transplant rejection.

1/3




Fig. 1. Effect of 2,9-diaminodecanedioic acid (R6) on proliferation of IL-15-stimulated PBMC.




Fig. 2. Effect of 2,9-diaminodecanedioic acid (R6) on proliferation of IL-2-stimulated PBMC.

2/3




Fig. 3. Effect of 2,9-diaminodecanedioic acid (R6) on IL-15-induced TNF- α synthesis in PBMC.




Fig. 4. Effect of 2,9-diaminodecanedioic acid (R6) on IL-2-induced TNF- α synthesis in PBMC.

3/3




Fig. 5. Effect of 2,9-diaminodecanedioic acid (R6) on IL-15-induced IL-17 synthesis in PBMC.




Fig. 6. Effect of 2,9-diaminodecanedioic acid (R6) on IL-2-induced IL-17 synthesis in PBMC.

INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2014/001939

A. CLASSIFICATION OF SUBJECT MATTER

INV. A61K31/20 A61P37/06 A61P17/06 A61P19/02 A61P29/00
A61P13/00
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS, CHEM ABS Data, EMBASE, WPI Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2012/082640 A1 (HANSON GUNNAR J [US] ET AL) 5 April 2012 (2012-04-05) abstract paragraphs [0243], [0366] page 26; example 7 page 33; example 2 page 34; examples 4,6 page 35; example 8	1,4-9
A	JP 2010 168290 A (YAMADA BEE FARM CORP) 5 August 2010 (2010-08-05) abstract paragraphs [0008], [0010], [0021], [0022], [0065] - [0071] claims ----- -/-	1-9

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

13 January 2015

Date of mailing of the international search report

27/01/2015

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Garabatos-Perera, J

INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2014/001939

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2004/247604 A1 (COHEN IRUN R [IL] ET AL) 9 December 2004 (2004-12-09) abstract paragraphs [0008], [0010], [0011], [0028] claims	1-9
A	----- EP 2 354 152 A1 (CT INGENIERIA GENETICA BIOTECH [CU]) 10 August 2011 (2011-08-10) abstract claims -----	1-9

1

Form PCT/ISA/210 (continuation of second sheet) (April 2005)

page 2 of 2

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/IB2014/001939

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2012082640 A1	05-04-2012	AU 2007254033 A1 BR PI0708942 A2 CA 2646186 A1 EP 1996184 A2 JP 2009530424 A US 2008051389 A1 US 2012082640 A1 US 2013281385 A1 WO 2007136921 A2	29-11-2007 14-06-2011 29-11-2007 03-12-2008 27-08-2009 28-02-2008 05-04-2012 24-10-2013 29-11-2007
JP 2010168290 A	05-08-2010	JP 5478082 B2 JP 2010168290 A	23-04-2014 05-08-2010
US 2004247604 A1	09-12-2004	AT 453409 T CA 2442943 A1 CN 1514736 A EP 1408951 A2 HU 0303796 A2 IL 158226 A JP 2004526757 A KR 20030096311 A MX PA03009342 A NO 20034557 A NZ 528783 A PL 366696 A1 US 2004247604 A1 WO 02083058 A2 ZA 200307784 A	15-01-2010 24-10-2002 21-07-2004 21-04-2004 01-03-2004 03-11-2008 02-09-2004 24-12-2003 12-02-2004 05-12-2003 28-10-2005 07-02-2005 09-12-2004 24-10-2002 06-10-2004
EP 2354152 A1	10-08-2011	AU 2009298304 A1 CA 2738744 A1 CN 102203118 A CU 23716 A1 EP 2354152 A1 JP 2012503976 A KR 20110095238 A RU 2011117356 A US 2011251140 A1 WO 2010037351 A1	08-04-2010 08-04-2010 28-09-2011 05-10-2011 10-08-2011 16-02-2012 24-08-2011 10-11-2012 13-10-2011 08-04-2010

Form PCT/ISA/210 (patent family annex) (April 2005)